Blog

‘Unheard of’ responses to bluebird CAR-T therapy seen in myeloma study – Reuters


Endpoints News

'Unheard of' responses to bluebird CART therapy seen in myeloma study
Reuters
“This is unheard of, something that we haven't seen with any drugs approved for myeloma in this type of population. The excitement among all the myeloma providers is crazy,” said Berdeja, director of myeloma research at the Sarah Cannon Center for
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 …Business Wire (press release)


BCMA-Directed bb2121 Highly Effective for MyelomaOncLive

all 5 news articles »

2017-12-10 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.